Stock Scorecard



Stock Summary for Mesoblast Ltd (MESO) - $14.70 as of 8/12/2025 1:29:03 PM EST

Total Score

4 out of 30

Safety Score

23 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for MESO

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for MESO

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for MESO

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for MESO

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for MESO (23 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for MESO

Mesoblast Limited ( MESO ) Is Up 40.59% in One Week: What You Should Know 7/22/2025 4:00:00 PM
Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday - Applied Digital ( NASDAQ:APLD ) 7/18/2025 2:03:00 PM
Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - BioNexus Gene Lab ( NASDAQ:BGLC ) , 180 Life Sciences ( NASDAQ:ATNF ) 7/18/2025 10:34:00 AM
Successful Commercial Launch of Ryoncil® 7/18/2025 12:38:00 AM
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - BrightView Hldgs ( NYSE:BV ) , ArriVent BioPharma ( NASDAQ:AVBP ) 7/2/2025 12:22:00 PM
Why Greenbrier Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - Argo Blockchain ( NASDAQ:ARBK ) 7/2/2025 9:55:00 AM
Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday - Advance Auto Parts ( NYSE:AAP ) , ATAI Life Sciences ( NASDAQ:ATAI ) 7/1/2025 2:38:00 PM
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Mesoblast ( NASDAQ:MESO ) 7/1/2025 12:46:00 PM
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure 7/1/2025 12:36:00 AM
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Aptevo Therapeutics ( NASDAQ:APVO ) , AIRO Group Holdings ( NASDAQ:AIRO ) 6/20/2025 12:01:00 PM

Financial Details for MESO

Company Overview

Ticker MESO
Company Name Mesoblast Ltd
Country USA
Description Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 12/31/2024
Next Earnings Date 8/27/2025

Stock Price History

Last Day Price 14.70
Price 4 Years Ago 9.60
Last Day Price Updated 8/12/2025 1:29:03 PM EST
Last Day Volume 109,204
Average Daily Volume 268,926
52-Week High 22.00
52-Week Low 6.00
Last Price to 52 Week Low 145.00%

Valuation Measures

Trailing PE N/A
Industry PE 34.75
Sector PE 56.71
5-Year Average PE -24.92
Free Cash Flow Ratio 49.00
Industry Free Cash Flow Ratio 19.95
Sector Free Cash Flow Ratio 30.71
Current Ratio Most Recent Quarter 0.96
Total Cash Per Share 0.30
Book Value Per Share Most Recent Quarter 0.40
Price to Book Ratio 4.17
Industry Price to Book Ratio 18.89
Sector Price to Book Ratio 28.44
Price to Sales Ratio Twelve Trailing Months 340.12
Industry Price to Sales Ratio Twelve Trailing Months 48.29
Sector Price to Sales Ratio Twelve Trailing Months 37.85
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 127,942,000
Market Capitalization 1,880,747,400
Institutional Ownership 3.11%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -7.41%
Reported EPS 12 Trailing Months -1.24
Reported EPS Past Year -0.32
Reported EPS Prior Year -0.13
Net Income Twelve Trailing Months -103,351,000
Net Income Past Year -87,956,000
Net Income Prior Year -81,889,000
Quarterly Revenue Growth YOY -6.80%
5-Year Revenue Growth -18.80%
Operating Margin Twelve Trailing Months -633.00%

Balance Sheet

Total Cash Most Recent Quarter 38,029,000
Total Cash Past Year 62,563,000
Total Cash Prior Year 70,920,000
Net Cash Position Most Recent Quarter -62,454,000
Net Cash Position Past Year -37,920,000
Long Term Debt Past Year 100,483,000
Long Term Debt Prior Year 102,811,000
Total Debt Most Recent Quarter 100,483,000
Equity to Debt Ratio Past Year 0.83
Equity to Debt Ratio Most Recent Quarter 0.82
Total Stockholder Equity Past Year 480,355,000
Total Stockholder Equity Prior Year 501,838,000
Total Stockholder Equity Most Recent Quarter 461,262,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -20,888,000
Free Cash Flow Per Share Twelve Trailing Months -0.16
Free Cash Flow Past Year -48,789,000
Free Cash Flow Prior Year -63,583,000

Options

Put/Call Ratio 0.06
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.84
MACD Signal 1.02
20-Day Bollinger Lower Band 8.26
20-Day Bollinger Middle Band 12.15
20-Day Bollinger Upper Band 16.05
Beta 1.32
RSI 55.06
50-Day SMA 12.46
150-Day SMA 7.72
200-Day SMA 7.83

System

Modified 8/12/2025 4:53:20 AM EST